Table 3 Characteristics of patients with and without recurrence in breast conserving group
Variable | Recurrence (n=6) | No recurrence (n=121) | P |
|---|---|---|---|
Age (yr) | 46.2±6.9 | 48.5±8.9 | .697 |
≤40 | 1(16.7%) | 17(14.0%) | |
41-60 | 5(83.3%) | 91(75.2%) | |
≥61 | 0 | 13(10.7%) | |
Tumor size (mm) | 51.4±28.0 | 23.5±19.1 | .000 |
≤15 | 0 | 58(47.9%) | |
16-40 | 1(16.7%) | 42(34.7%) | |
≥41 | 5(83.3%) | 21(17.4%) | |
Tumor grade | .033 | ||
1 | 0 | 28(23.1%) | |
2 | 2(33.3%) | 67(55.4%) | |
3 | 4(66.7%) | 26(21.5%) | |
Margin (mm) | 10.6±8.6 | 9.4±7.6 | .314 |
>9 | 4(66.7%) | 46(38.0%) | |
1-9 | 2(33.3%) | 57(47.1%) | |
<1 | 0 | 18(14.9%) | |
Multifocality | .201 | ||
Yes | 2(33.3%) | 16(13.2%) | |
No | 4(66.7%) | 105(86.8%) | |
Receptor status | .031 | ||
ER positive | 2(33.3%) | 94(77.7%) | |
ER negative | 4(66.7%) | 27(22.3%) | |
PR positive | 2(33.3%) | 83(68.6%) | .092 |
PR negative | 4(66.7%) | 38(31.4%) | |
C-erbB2 | .354 | ||
0 | 0 | 16(13.2%) | |
1+ | 0 | 31(25.6%) | |
2+ | 3(50%) | 28(23.1%) | |
3+ | 3(50%) | 44(36.4%) | |
Unknown | 0 | 2(1.4%) | |
Ki67 (%) | .700 | ||
<10 | 2(33.3%) | 65(53.7%) | |
10-19 | 2(33.3%) | 22(18.2%) | |
≥20 | 2(33.3%) | 31(25.6%) | |
VNPI score | .260 | ||
4-6 | 0 | 38(31.4%) | |
7-9 | 5(83.3%) | 70(57.9%) | |
10-12 | 1(16.7%) | 13(10.7%) | |
Tamoxifen | 2(33.3%) | 93(76.9%) | .035 |
Radiation | 6(100.0%) | 89(73.6%) | .336 |